We hypothesize that the decrease in ABCG1 levels during the progression of RCC may suggest that the cholesterol transport-related molecule ABCG1 could be a potential target for ccRCC treatment. This evidence concerns the gene ABCG1 and nonpapillary renal cell carcinoma.